Clinical Trials Logo

Acute Kidney Injury clinical trials

View clinical trials related to Acute Kidney Injury.

Filter by:

NCT ID: NCT06378827 Recruiting - Acute Kidney Injury Clinical Trials

Intraoperative Dexmedetomidine and Coronary Artery Bypass Graft Surgery

Start date: April 3, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This is a prospective randomized clinical trial designed to determine the effect of intraoperative dexmedetomidine administration on renal function after coronary artery bypass graft surgery.

NCT ID: NCT06374797 Not yet recruiting - Acute Kidney Injury Clinical Trials

A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"

KOURAGE
Start date: May 2024
Phase: Phase 2
Study type: Interventional

Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.

NCT ID: NCT06372444 Not yet recruiting - Sepsis Clinical Trials

Mechanisms of Acute Kidney Injury in Severe Infections

PET-AKI
Start date: May 1, 2024
Phase:
Study type: Observational

Renal perfusion and neutrophil-mediated inflammation will be assessed in the kidney in sepsis patients with acute kidney injury using positron emission tomography. For marked water will be used for renal perfusion and a newly developed PET tracer molecule (11C-GW457427) with specific binding to neutrophil elastase which provides a measure of the amount of infiltrating neutrophils in the renal parenchyma for inflammation. The study is performed in a PET-CT camera where anatomical imaging takes place at the same time as the PET examinations.

NCT ID: NCT06369064 Not yet recruiting - Acute Kidney Injury Clinical Trials

Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient

CompEER
Start date: June 15, 2024
Phase: N/A
Study type: Interventional

In patients requiring renal replacement therapy (RRT) in the intensive care unit (ICU), continuous techniques are predominantly using due to better hemodynamic tolerance. The most employed techniques in ICU are continuous venovenous hemodiafiltration (CVVHDF) and continuous venovenous hemodialysis (CVVHD). To our knowledge, there are no prospective studies comparing the efficiency of these two techniques with the same dose of dialysis (and the same filter). In the CompEER study, we aim to compare the efficiency of CVVHD and CVVHDF on urea reduction rate in intensive care patients with acute kidney injury. The research hypothesis is that CVVHD citrate technique is as effective as CVVHDF heparin technique for urea reduction and provides prolonged and stable clearance, facilitating antibiotic management during RRT.

NCT ID: NCT06365827 Active, not recruiting - Acute Kidney Injury Clinical Trials

Perioperatively Assessed Biomarker I-FABP Level for Prediction of Acute Mesenteric Ischemia and Its Correlation With Acute Kidney Injury, Followed by Extracorporeal Circulation (aMIKI)

aMIKI
Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

Acute mesenteric ischemia (AMI) is a severe condition that might occur after cardiovascular surgery. Several risk factors for AMI, such as multimorbidity, the use of vasopressors, and an increase in inflammatory markers have been identified in the past. However, these risk factors also seem to influence the blood and urine levels of I-FABP. This prospective pilot study intends to evaluate the value of perioperatively assessed I-FABP levels and to correlate these values with clinical or angiographic findings in mesenteric ischemia to improve a standardised diagnosis.

NCT ID: NCT06358365 Completed - Clinical trials for Chronic Kidney Diseases

Enhancing Fluid Transfer Through the Skin, by Increased Sweat Rate, on Hemodialysis Patients

Start date: March 29, 2023
Phase: N/A
Study type: Interventional

To demonstrate safety and performance of AquaPass System for improving fluid balance in hemo-dialysis patients, by increasing fluid loss via the skin.

NCT ID: NCT06353659 Not yet recruiting - Acute Kidney Injury Clinical Trials

The Diagnostic Value of Contrast-enhanced Ultrasound in Acute Kidney Injury in ICU

Start date: April 15, 2024
Phase:
Study type: Observational

The goal of this observational study is to quantitatively assess the renal microcirculation changes by contrast-enhanced ultrasound (CEUS) and to obtain systemic hemodynamic information by ultrasound Doppler at the same time, to analyze the relationship between renal microcirculation changes and systemic hemodynamic changes, and to explore the diagnostic value of CEUS in critically ill acute kidney injury.

NCT ID: NCT06351813 Not yet recruiting - Critical Illness Clinical Trials

Predicting Adverse Kidney Events of Cardiac Surgery-Associated Acute Kidney Injury Using Novel Biomarkers

Start date: April 1, 2024
Phase:
Study type: Observational

The aim of this study was to identify and validate novel biomarkers for predict acute kidney injury (AKI) subphenotype, major adverse kidney events and other poor outcomes.

NCT ID: NCT06349577 Not yet recruiting - Surgery Clinical Trials

Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury

Start date: April 2024
Phase: N/A
Study type: Interventional

The objective is to determine the effectiveness of pulsatile flow during cardiopulmonary bypass to reduce the incidence of acute kidney injury after cardiac surgery. Investigators will also evaluate the safety and impact of pulsatile flow on clinical outcomes compared to non-pulsatile flow during cardiopulmonary bypass.

NCT ID: NCT06344442 Not yet recruiting - Clinical trials for Acute Kidney Injury Post Liver Transplantation

Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)

Start date: May 5, 2024
Phase: Phase 3
Study type: Interventional

Liver transplantation (LT) is a high-risk surgery for hemodynamic instability and haemorrhagic shock with a high-risk of acute kidney injury (AKI). Indeed, the incidence of post-transplant AKI exceeds 50% in some series with 15% of patients requiring renal replacement therapy. Acute kidney injury after LT is a predisposing factor for chronic renal failure which is independently associated with higher morbidity and mortality. Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension, binds to AVPR1a to promote vasoconstriction. Furthermore, it may have nephroprotective effects with a preferential vasoconstriction of the post-glomerular arteriole resulting in increased glomerular filtration The hypothesis of the present work is that low-dose arginine-vasopressin supplementation reduce posttransplant AKI in liver transplantation.